Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Frustration Intolerance Scale for Students.
Clin Psychol Psychother
January 2025
Department of Psychology, University of Oradea, Oradea, Romania.
Background: Frustration intolerance (FI) is the belief that reality should meet our desires for ease, pleasure and comfort. Although extensively studied in adults, tools for measuring FI in children and adolescents are scarce. The Frustration Intolerance Scale for Students (FISS) was developed to fill this gap.
View Article and Find Full Text PDFPercutaneous Cryoablation Therapy for Abdominal wall Endometriosis: a Systematic Review and Meta-analysis.
Br J Radiol
January 2025
Department of Medical Imaging, Hematology and Clinical Oncology, Ribeirão Preto Medical School-University of São Paulo, Ribeirão Preto, SP, Brazil.
Purpose: Abdominal wall endometriosis consists of endometrial tissue between the peritoneum and the abdominal wall. The established treatment involves amenorrheic drugs-not always successful and tolerated-or invasive surgery. In this scenario, minimally invasive techniques such as cryoablation are a potential option.
View Article and Find Full Text PDFSafety, Tolerability, and Pharmacokinetics of Long-Acting Broadly Neutralizing HIV-1 Monoclonal Antibody VRC07523LS in Newborn Infants Exposed to HIV-1.
J Pediatric Infect Dis Soc
January 2025
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH Bethesda, MD, USA.
Background: Vertical HIV-1 transmission despite antiretroviral therapy may be mitigated by use of long-acting, broadly neutralizing, monoclonal antibodies (bNAb) such as VRC07523LS. The present study was designed to determine the safety and pharmacokinetics of VRC07523LS.
Methods: VRC07523LS, 80 mg/dose, was administered subcutaneously after birth to non-breastfed (Cohort 1; N=11, enrolled in USA) and breastfed (Cohort 2; N=11, enrolled in South Africa and Zimbabwe) infants exposed to HIV-1.
Efficacy and tolerability of neoadjuvant therapy with Talimogene laherparepvec in cutaneous basal cell carcinoma: a phase II trial (NeoBCC trial).
Nat Cancer
January 2025
Medical University of Vienna, Department of Dermatology, Vienna, Austria.
We present a single-arm, phase II, neoadjuvant trial with the oncolytic virus talimogene laherparepvec (T-VEC) in 18 patients with difficult-to-resect cutaneous basal cell carcinomas. The primary end point, defined as the proportion of patients, who after six cycles of T-VEC (13 weeks), become resectable without the need for plastic reconstructive surgery, was already achieved after stage I (9 of 18 patients; 50.0%); thus the study was discontinued for early success.
View Article and Find Full Text PDFXanomeline-trospium (Cobenfy) for Schizophrenia: A Review of the Literature.
Clin Psychopharmacol Neurosci
February 2025
Department of Pharmacy Practice, Campbell University College of Pharmacy and Health Sciences, Buies Creek, NC, USA.
Schizophrenia is a chronic and severe mental illness associated with substantial morbidity and mortality. Antipsychotics primarily rely on direct dopamine blockade, leading to potential life-interfering adverse events. The purpose of this review is to describe the safety and efficacy of xanomeline-trospium (Cobenfy), a Food and Drug Administration approved treatment for schizophrenia in adults.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!